Syros Pharmaceuticals Inks $30M Series A

Syros Pharmaceuticals, which is focused on treatments for cancer and other diseases, has inked $30 million in Series A financing. Company co-founders ARCH Venture Partners and Flagship Ventures led the round. The money will go toward development of novel gene control medicines.

North AmericaUSBriefs